1,699 reports of this reaction
1.9% of all DAPAGLIFLOZIN reports
#10 most reported adverse reaction
ACUTE KIDNEY INJURY is the #10 most commonly reported adverse reaction for DAPAGLIFLOZIN, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,699 FDA adverse event reports linking DAPAGLIFLOZIN to ACUTE KIDNEY INJURY. This represents approximately 1.9% of all 89,435 adverse event reports for this drug.
Patients taking DAPAGLIFLOZIN who experience acute kidney injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE KIDNEY INJURY is a less commonly reported adverse event for DAPAGLIFLOZIN, but still significant enough to appear in the safety profile.
In addition to acute kidney injury, the following adverse reactions have been reported for DAPAGLIFLOZIN:
The following drugs have also been linked to acute kidney injury in FDA adverse event reports:
ACUTE KIDNEY INJURY has been reported as an adverse event in 1,699 FDA reports for DAPAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE KIDNEY INJURY accounts for approximately 1.9% of all adverse event reports for DAPAGLIFLOZIN, making it a notable side effect.
If you experience acute kidney injury while taking DAPAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.